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Efficacious therapies are available to control Hepatitis B Virus (HBV) and 
Hepatitis C Virus (HCV) infections but no valid therapy has been developed against the 
Hepatitis D Virus (HDV); Interferon alpha (IFN) remains the only licensed therapy 30 
years after it was empirically introduced in clinical practice on the wake of its use as a 
panacea for all types of viral hepatitis. 
The overall results with standard IFN were poor
1
. At a dose of 3 to 6 million units (MU) 
thrice weekly for 6 to 12 months treatment controlled liver enzymes in no more than 
20%- 25% of the patients; rates of HDV-RNA clearance were lower. Results were 
worse in cirrhotics. The studies were difficult to compare; they were heterogeneous, had 
different designs and protocols, each examined only a small number of patients, testing 
for HDV-RNA was performed with homemade nucleic acid hybridisation assays of 
limited sensitivity and specificity.  
Long-acting Peg-IFNs have increased efficacy only marginally. In four studies
2-3
, a 
virologic response was observed in 18% to 25% of the patients; only in a series of 14 
patients the response rate was 43%
4
. Increasing the dosage of IFN, prolonging therapy 
to 24 months, adding an antiviral against the HBV or Ribavirin to Peg-IFN was of no 
advantage
2
. All studies considered as therapeutic end-point the virologic response six 
months post-therapy, following the paradigm of the sustained virologic response (SVR) 
derived from the experience with HCV disease, where SVR is a surrogate of cure. No 
study performed with the current standard of care, i.e. Peg-IFN, addressed 
systematically the long-term virological and clinical outcome of treated HDV patients. 
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The issue of the therapy for chronic hepatitis D has been reconsidered in a 
number of comprehensive studies performed by a German-Turkish-Greek Consortium 
on behalf of the Hep-Net International Delta Hepatitis Intervention Trial (HIDIT-I). 
They have included the larger number of HDV patients treated so far and have 
analysed in structured and well-designed investigations all the factors influencing 
therapy that had emerged from previous studies. 
In a first study published in 2011
5
, 90 patients were randomly assigned to receive either 
180 µg Peg-IFN alfa each week plus 10 mg of adefovir (31 patients), 180 µg/kg Peg-
IFN-α2a plus placebo (29 patients) or adefovir alone (30 patients). By week 48 of 
therapy, the reduction of HDV RNA was higher and similar in the two groups using 
Peg-IFN compared with adefovir alone; overall HDV RNA was negative in 28% of 
patients given Peg-IFN compared with only 8% of the patients given adefovir alone. 
The SVR rate of 28% confirmed that Peg-IFN may be efficacious in about one 
fourth of treated patients. The study confirmed also that a potent HBV antiviral like 
Adefovir had no therapeutic role, either alone or in combination with IFN. Nevertheless 
the impact of therapy on liver disease was not consistent; more patients in the Peg-IFN 
groups had a worsening of histologic scores on biopsies performed at the end of 
treatment and the levels of alanine aminotransferase normalized also in patients who 
remained positive for HDV-RNA during the follow-up.  
A second piece of the HIDIT-I mosaic has been published in the July number of 
Hepatology
6
, where Heidrich, and co-workers report the outcome over the long-term of 
HDV patients treated in the first HIDIT-I study. This information is critical in order to 
assess the true efficacy of Peg-IFN therapy; although relapses of HD viremia and 
hepatitis D after apparently successful therapy were repeatedly noted 
1,7
 using first-
generation insensive assays for serum HDV-RNA, the report by Heidrich is the first to 
systematically determine the extent and impact of late post-therapy relapses of HDV 
using an PCR assay with a sensitivity as low as 15 cps HDV-RNA/ml. 
Long-term follow-up data were available for 58 of 77 patients (75%) who completed 
the HIDIT-I trial. The median time of follow-up was 4.5 years. Of 16 patients with 




undetectable HDV-RNA six months post-therapy, 9 (56%) tested positive at least once 
during the post-therapy follow-up and 7 of them tested positive at the last visit. 
Sequencing confirmed the reappearance of the original virus strain in all cases. The 
virologic relapses were associate with ALT increases in at least four subjects. 
Six patients lost the HBsAg; two of the five for whom data were available, 
seroconverted to anti-HBs. Interestingly, in the long-term virologic responders, serum 
HBsAg had decreased at week 48 of therapy by a mean 1.6 log IU/ml while in 
individuals with late relapses, HBsAg levels showed an increase of 1.0 log 10/ml. 
 
The data of Heidrich provide a dimension to the problem of late HDV relapses 
after therapy. With a figure of 56%, the dimension is so consistent to challenge and 
dismiss the belief that a SVR for HDV-RNA six months post therapy is a surrogate of 
cure of hepatitis D. 
Why is HDV infection so prone to relapse? As hepatitis D results from the double 
infection with HBV and HDV, the definition of therapeutic goals requires that both 
infections are considered. HDV is highly infectious in the setting of an established HBV 
infection, the HBsAg acting as a magnet that attracts and activates infinitesimal 
amounts of the virus; HDV was transmitted to chimpanzees carrying the HBsAg with 




.    
The most sensitive current assays for the measure of HDV-RNA have a detection limit 
of 10 viral genomes/ml
9
; their sensitivity is far lower than the natural infectivity 
threshold of HDV for the HBsAg carrier, therefore clearance of HDV-RNA determined 
with these assays does not warrant that infectious virus has been eradicated. This means 
that in patients who achieve a SVR with IFN but remain HBsAg-positive, residual 
undetectable HDV may be rescued to reactivate hepatitis D any time after an apparently 
successful therapy. Clearly the ultimate goal of therapy would be the elimination of the 
HBsAg; this is the only reliable end-point indicative of cure of HDV, but unfortunately 
it is seldom attained.  
 




The HIDTI-I studies have confirmed that hepatitis D is the form of viral hepatitis 
most difficult to treat.  
Why is hepatitis D so difficult to cure? The disease could be cured by eradication 
of either the HBV or the HDV but unfortunately neither goal is attainable at present. 
In ordinary virology therapeutic efforts are targeted against the replicative machinery of 
the infecting virus. However, HDV is no ordinary virus and offers no target to antiviral 
attack; it is too small to code for the complex proteins required for independent 
replication and relies entirely on the replicative machinery of the hepatocytes for its 
synthesis
10
. Potent antivirals are now available to control the synthesis of HBV-DNA, 
but HDV requires from the partner virus no function linked to the replication of HBV-
DNA. It requires only the HBsAg capsid to penetrate hepatocytes and propagate 
infection
11
; as long as the HBsAg is expressed by the covalently closed circular HBV-
DNA protected from antiviral attack in the nuclei, HDV can thrive regardless of the 
inhibition of the synthesis of HBV-virions. 
 
The recommendation to treat chronic hepatitis D with Peg-IFN is supported by 
the marginal advantages emerged from short-term trials and by claims of long-term 
benefit from anecdotal case reports and uncontrolled small series. Management is based 
on accepted common practice. Peg-IFN is scheduled weekly for 48 weeks followed by 
6 months observation post-therapy; patients who remain negative for HDV-RNA are 
considered to have eliminated the HDV
12
. The recommendation and  practice are 
disputed by the HIDIT-I studies, which have shown that the response to Peg-IFN at the 
classical SVR end-point is ephemeral, that evaluation of efficacy requires a much 
longer follow-up, and that the overall efficacy is distinctly less then currently perceived. 
In the Heidrich paper
6
, the relapses within 4 years decreased the rate of clearance of 
HDV-RNA to less than half the response reached by the original HIDIT-I trial at SVR. 
Of note, the other patients who maintained the SVR cannot be considered cured of 
HDV; they remain at risk of a HDV relapse as long as they harbour the HBsAg. Only 




the 10% of the patients who cleared the HBsAg appear to be unequivocally cured of 
HDV.  
 
The ultimate message is that the current therapeutic end-goals of Peg-IFN therapy 
for chronic hepatitis D are misleading and the therapeutic approach should be  
reconsidered anew. To increase efficacy, therapy could be given for longer durations. 
However in a third piece of the HIDIT-I mosaic, relapses of HDV post-therapy were not 
prevented even by 96 weeks of Peg-IFN therapy, alone or in combination with 
Tenofovir
13
; 24 weeks post-therapy relapses occurred in 39% of the on-treatment 
responders to Peg-IFN monotherapy and in 36% of those give the combination. 
Prolonging therapy over two years would raise major problems of tolerance and 
compliance. More realistically, patients treated with Peg-IFN according to the current 
timetables, should be monitored long-term not only for HDV-RNA but also for 
quantitative HBsAg. To push for eradication, long-term therapy could be considered in 
the patients who clear the HDV-RNA and exhibit a significant decline of HBsAg during 





Treatment of chronic hepatitis D with Peg-IFN is becoming more complex and 
even less appealing; new therapeutic strategies are urgently needed.  
The lack of a standard HDV-RNA reference has been so far a major problem in 
evaluating therapeutic efficacy. Many laboratories have developed in-house assays with 
various protocols using primers in the conserved hepatitis D antigen or ribozyme 
region, but results are not comparable due to different sensitivities and specificities . 
The good news is that at last an international calibration standard has been 
developed and is now available to standardize HDV loads in serum and plasma
17
. 
Therapy of chronic hepatitis D remains a formidable challenge. The HDV offers 
no specific viral target to antiviral therapy and current therapeutic efforts are directed to 




prevent the uptake by the liver of the HDV virion or prevent intrahepatic virion 
assembly.  
Myrcludex B, a synthetic N-acylated preS1 lipopeptide, holds a promise; by interfering 
with the binding of the myristoylated N-terminal pre-S1 domain of the HBsAg with the 
recently identified sodium taurocholate cotransporting polypeptide receptor for HBV
18
, 
it was shown in vivo and in vitro to block the entry of HDV into the hepatocytes
19
. 
The oral prenylation inhibitor lonafarnib which inhibits the combination of the large 
HD antigen with the HBsAg necessary for HDV assembly is under evaluation in an 
NIH study whose results are eagerly awaited
20
. More futuristic approaches currently in 
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